Categories Consumer, Earnings Call Transcripts

Universal Corp. (UVV) Q3 2022 Earnings Call Transcript

UVV Earnings Call - Final Transcript

Universal Corp.  (NYSE: UVV) Q3 2022 earnings call dated Feb. 02, 2022

Corporate Participants:

Candace Formacek — Vice President and Treasurer

Analysts:

Ann Gurkin — Davenport & Company LLC — Analyst

Chris Reynolds — Neuberger Berman — Analyst

Presentation:

Operator

Good evening. Thank you for attending today’s Universal Corporation Third Quarter Fiscal Year 2022 Earnings Conference Call. My name is Tinea, and I will be your moderator for today’s call. [Operator Instructions].

I would now like to pass the conference over to our host Candace Formacek, Vice President and Treasurer. Please go ahead.

Candace Formacek — Vice President and Treasurer

Thank you, Tinea. And thank you all for joining us. George Freeman, our Chairman, President and CEO; Airton Hentschke, our Chief Operating Officer; and Johan Kroner, our Chief Financial Officer, are here with me today and will join me in answering questions after these brief remarks. This call is being webcast live and will be available on our website and on telephone taped replay. It will remain on our website through May 2, 2022. Other than the replay, we have not authorized and disclaim responsibility for any recording, replay or distribution of any transcription of this call. This call is copyrighted and may not be used without our permission.

Before I begin to discuss our results, I caution you that we will be making forward-looking statements that are based on our current knowledge and some assumptions about the future and are representative as of today only. Actual results could differ materially from projected or estimated results and we assume no obligation to update any forward-looking statements. This is of particular note during the current ongoing COVID-19 pandemic, when the length and severity of the crisis and resultant economic and business impacts are so difficult to predict.

For information on some of the factors that can affect our estimates, I urge you to read our 10-K for the year ended March 31, 2021, and the Form 10-Q for the most recently ended fiscal quarter. Such risks and uncertainties include, but are not limited to, the ongoing COVID-19 pandemic, customer-mandated timing of shipments, weather conditions, political and economic environment, government regulation and taxation, changes in exchange rates and interest rates, industry consolidation and evolution, and changes in market structure or sources.

Finally, some of the information I have for you today is based on unaudited allocations and is subject to reclassification. In an effort to provide useful information to investors, our comments today may include non-GAAP financial measures. For details on these measures, including reconciliations to the most comparable GAAP measures, please refer to our current earnings press release.

Our operations produced solid results in the 9 months ended December 31, 2021. We are especially pleased by the strong results from our Ingredients Operations segment. That segment is developing nicely and was bolstered by our acquisition of Shank’s Extracts, Inc. Shank’s, on October 4, 2021. Shank’s adds valuable capabilities to the segment, including flavors and extracts, custom packaging, bottling, and product development.

We continued to experience the impact of tobacco shipment timing on our results in the 9 months and quarter ended December 31, 2021. Tobacco shipments through the 9 months ended December 31, 2021, were lower, compared to the same period in fiscal year 2021, in part due to elevated tobacco shipments in the third quarter of fiscal year 2021 related to earlier customer mandated shipment timing. Logistical challenges due to continued limitations in worldwide shipping availability stemming from the ongoing COVID-19 pandemic also slowed tobacco shipments in the 9 months ended December 31, 2021. However, despite the shipment timing variations and logistical challenges, we believe that our tobacco business remains robust with strong customer demand, and our uncommitted tobacco inventory levels remain well within our target range.

Turning to the results. Net income for the 9 months ended December 31, 2021, was $60.8 million, or $2.44 per diluted share, compared with $48 million, or $1.94 per diluted share, for the 9 months ended December 31, 2020. Excluding restructuring and impairment costs and certain other non-recurring items, detailed in other items in today’s earnings release, net income and diluted earnings per share increased by $4.5 million and $0.17, respectively, for the 9 months ended December 31, 2021, compared to the 9 months ended December 31, 2020. Adjusted operating income, also detailed in other items of $116.5 million increased by $8.9 million for the 9 months ended December 31, 2021, compared to adjusted operating income of $107.6 million for the 9 months ended December 31, 2020.

Net income for the quarter ended December 31, 2021, was $34.9 million, or $1.40 per diluted share, compared with $33.3 million, or $1.34 per diluted share, for the quarter ended December 31, 2020. Excluding restructuring and impairment costs and certain other non-recurring items, detailed in other items in today’s earnings release, net income and diluted earnings per share decreased by $9.7 million and $0.39, respectively, for the quarter ended December 31, 2021, compared to the quarter ended December 31, 2020. Adjusted operating income, also detailed in other items, of $74.9 million decreased by $10.4 million for the third quarter of fiscal year 2022, compared to adjusted operating income of $85.2 million for the third quarter of fiscal year 2021.

Consolidated revenues increased by $90.9 million to $1.5 billion for the 9 months ended December 31, 2021, compared to the same period in the prior fiscal year, on the addition of the businesses acquired in the Ingredients Operations segment and a better product mix and higher sales prices in the Tobacco Operations segment.

In the quarter ended December 31, 2021, consolidated revenues decreased by $20.3 million to $652.6 million, compared to the quarter ended December 31, 2020, on lower tobacco sales volumes offset in part by a better tobacco product mix and higher tobacco sales prices as well as the inclusion of the Shank’s acquisition in the Ingredients Operations segment.

Turning to the segments. Tobacco Operations. Operating income for the Tobacco Operations segment decreased by $2.1 million to $105.6 million and by $14.3 million to $69.8 million, respectively, for the 9 months and quarter ended December 31, 2021, compared to the same periods in fiscal year 2021. Tobacco Operations segment results declined largely due to tobacco shipment timing, partially offset by a favorable product mix consisting of a higher percentage of lamina tobacco as well as increased value-added services to customers in the 9 months and quarter ended December 31, 2021, compared to the 9 months and quarter ended December 31, 2020.

Africa sales volumes were lower in the 9 months and quarter ended December 31, 2021, compared to the same periods in the prior fiscal year, on smaller burley crops as well as slower shipment timing. Sales volumes for Brazil were lower in the 9 months ended December 31, 2021, compared to the same period in the prior year, when high volumes of lower margin carryover tobaccos shipped. Vessel and container availability has also been limited in Brazil in fiscal year 2022, which has slowed shipments.

In Asia, although trading volumes were down on high freight costs, our operations saw a more favorable product mix, as well as increased value-added services for customers during the 9 months and quarter ended December 31, 2021, compared to the same periods in the prior fiscal year. Our operations in Europe experienced higher energy costs in the quarter and 9 months ended December 31, 2021, compared to the same periods in the prior fiscal year.

Selling, general, and administrative expenses for the Tobacco Operations segment were higher in the 9 months and quarter ended December 31, 2021, compared to the same periods in the previous fiscal year, primarily on unfavorable foreign currency exchange comparisons, mainly from noncash remeasurement.

Ingredients Operations. Operating income for the Ingredients Operations segment was $10.6 million and $3.5 million, respectively, for the nine months and quarter ended December 31, 2021, compared to operating losses in the prior fiscal year of $4.7 million and $2.5 million, respectively, for the 9 months and quarter ended December 31, 2020. Results for the segment include our October 2020 acquisition of Silva International, Inc. Silva, and our October 2021 acquisition of Shank’s. For both the 9 months and quarter ended December 31, 2021, our Ingredients Operations saw strong volumes in both human and pet food categories as well as some rebound in demand from sectors that have been impacted by the ongoing COVID-19 pandemic.

In addition, the segment saw strong sales of organic-based products, certain dehydrated products, and flavors and extracts. Selling, general, and administrative expenses for the segment increased in the 9 months and quarter ended December 31, 2021, compared to the same periods in the prior fiscal year, on the addition of the acquired businesses.

Our businesses have performed well managing global supply chain constraints, particularly shipping availability. However, due to continued lack of containers, trucks, and vessels in certain geographies, we expect that some tobacco shipments from certain origins will be pushed into fiscal year 2023. Inflationary pressures including higher freight and labor expenses have driven up our costs in both our tobacco and ingredients operations. We are also seeing higher raw materials costs for both tobacco and ingredients products, and we have been working diligently to build these increased costs into our product costs and customer contracts. Despite rising prices, we believe demand remains strong for both our tobacco and ingredients products. While it is still very early, we are also forecasting smaller crops in several key origins for fiscal year 2023.

And finally, sustainability has long been a core tenant of how we conduct our business, and we work to clearly communicate our sustainability goals and efforts. We published our fiscal year 2021 Sustainability Report in December 2021, and it is available on our website, www.universalcorp.com. We are excited about our measurable sustainability goals and targets outlined in the report and are committed to continue to build on our global sustainability programs to reinforce the sustainability of our supply chains.

At this time, we’re available to take your questions.

Questions and Answers:

Operator

Thank you. [Operator Instructions]. The first question is from the line of Ann Gurkin with Davenport. Your line is open.

Ann Gurkin — Davenport & Company LLC — Analyst

Hello everybody, good evening.

Candace Formacek — Vice President and Treasurer

Hi, Ann.

Ann Gurkin — Davenport & Company LLC — Analyst

I wanted to start with your comments and the release about some tobacco shipments from some origins will be pushed into fiscal ’23. Can you quantify that? And then is some the same as significant or less than significant that you may be targeted last press release? Can you help me at all with that?

Unidentified Speaker —

Yes, Ann, it will be very difficult to say at this point in time exactly how much of it [Technical Issues] to ’23. Lead times have to get bookings are, have gone to 6 weeks, container availability, shipping lanes actually going to the ports that they’re supposed to go to is questionable. So at this point in time, we just wanted to put it out there that there is a very good likelihood that we are going to see it, we just cannot quantify it at this point in time.

Ann Gurkin — Davenport & Company LLC — Analyst

So have you reached out and confirmed schedules as best as you can with existing customers or schedule still kind of in flux in terms of securing these vessels. Any other detail?

Unidentified Speaker —

Yes, look we have had constant communication with our customers to ensure that they are getting the tobaccos that they need. But, again, we are depending on the shipping lines to take the containers that are at port onto their vessel, sometimes those vessels just completely bypass some of the ports or they just leave containers at ports. So it’s difficult for us, of course, then we automatically going to put it on the next boat that gets there, but still, that’s where the difficulties in estimating exactly what those numbers are. And we will have to see what is going to be pushed into ’23, but we just wanted to put it out there, that it’s a very likely possibility that, that will happen.

Ann Gurkin — Davenport & Company LLC — Analyst

But this is committed volume, it’s just the timing factor?

Unidentified Speaker —

Yes. Again, we are very happy with the committed volume numbers that we have put out there. You can see we’re right in the middle of the range, we’re at 15%, which we’re very happy with that from last year. So all of that demand is great. So, no issues there whatsoever. There is a strong robust demand for the product. Just the question is can we get it on the boats? We can now to get it to our customers prior to year end.

Ann Gurkin — Davenport & Company LLC — Analyst

Fair enough. Okay, then your outlook for crops, forecasting potentially smaller crops in ’23, it looks like burley is headed for another relatively I think historically small crop year, so the third one in a row here. So you’re looking for burley to tighten again in ’23? Or what’s going to happen with the burley I would think customers will start getting nervous to secure enough supply of needed leaf given that we’re going into another smaller crop year.

Unidentified Speaker —

Ann, what we have seen in the last few weeks, a couple of months, some extreme weather conditions that are adversely impacting the projected volume that we have. And that’s of course is it’s still early in some areas. Tobacco — in Brazil, the crop is basically done but in Africa, the tobacco is in the growing period. So we’re still going to see a couple of months from now, what the final effect is. But we do see a tight market conditions for some tobacco styles and quality. And it’s we don’t see that just on the burley, we see that on the flue-cured and on the oriental market as well.

Ann Gurkin — Davenport & Company LLC — Analyst

Okay. Looking into our investor presentation in November, Slide 21 which is the operating margin. It looks like there is a nice recovery in ’21. How should we think about recovery? Or can you have continued recovery in fiscal ’22? What is your target operating margin range for the company? Any details there?

Unidentified Speaker —

You know as well enough, Ann, that we are not going to provide numbers. But, again —

Ann Gurkin — Davenport & Company LLC — Analyst

I try every quarter.

Unidentified Speaker —

[Speech Overlap]. Ann, we really understand the question. It’s — we saw some nice changes in the margins with regard to mix, which helped and we saw certainly some value-added business that we have in the Tobacco. The Ingredients should help there as well. And so it looks like a positive trend with regard to the margins.

Ann Gurkin — Davenport & Company LLC — Analyst

Nine months number looks like a nice trend. It’s just cannot hold given timing of shipments for the full year?

Unidentified Speaker —

If that remains to be seen, there is a couple of things in there, that we still have some tobacco to be shipped, some broadly still need to be shipped. So those are all positive. So again with all the things [Phonetic] about on the mix. And again ingredients if some of those freight costs go down, that’s certainly will help them as well because we saw a bit of compression there with regard to the margin. So, there is certainly some upside still to be add there.

Ann Gurkin — Davenport & Company LLC — Analyst

Okay, great. And then the next slide. I don’t like the trend in Slide ’22 in our presentation, the free cash flow trend. I’m not a fan of that and the net debt target. What’s the target, it’s up to 25% in ’21. What are your targets there? How should we think about that looking out a couple of years?

Unidentified Speaker —

Ann, again, we’re not going to point exactly through internal target but what we’re looking at of course is with the new acquisition certainly leverage has gone up, so we will be looking at that very closely to make sure that it doesn’t go too far out of bounds. Rating agencies, we’re having constant, say and our constant communication with them. And the ratings were confirmed although S&P put us on a negative outlook. So we’ll be looking at that leverage going forward here a little bit and see where we can bring it down a little bit to ensure that we can do the things that we want to do.

Unidentified Speaker —

And maintain our rating.

Ann Gurkin — Davenport & Company LLC — Analyst

Fair enough. And then switching to the Ingredients business. It’s nice to see a margin on that business for the quarter and the 9 months. Where should I think about the margin objective for that business and a more favorable operating environment without these freight issues?

Unidentified Speaker —

Yes, look, Ann, it’s a bit muddy still right, you still have some, if you look at the comparisons and everything from last year, you still have to stepping in there. And then now you have only one quarter of changes in their shelf. It’s quite muddy to look at it. So you needed to wait a couple of more quarters. And then you will get a clear picture of what we’re looking at, but again it’s value-added business where margins are nice and healthy and that’s where we think we can create shareholder value.

Ann Gurkin — Davenport & Company LLC — Analyst

And any impact on the pace of recovery in the business from omicron ended December, January, are you seeing any kind of pullback in demand, frankly on the human food side because of omicron like the pace of recovery?

Unidentified Speaker —

No. Look, omicron really has done little with regard to those businesses and started early on where you saw a bit of a shift because of where the product was being used, whether or not it was in the entertainment type bar setting or it was going to grocery stores or a bit of a shift there, that mix has gone back a little bit. So that’s all good. So, omicron is not really the issue. It’s really currently the freight and inflationary pressures with regard to labor cost and the freight cost that are out there.

And then in certain areas, we are using dehydrated product. On the tobacco side you have sheet product which you use a lot of heat and a lot of gas. So, energy prices have had an impact on those, but again those are the type of things that we’re looking at that trends positive.

Ann Gurkin — Davenport & Company LLC — Analyst

Okay, great. It looks like you pulled back on capex a little bit. What are the reasons?

Unidentified Speaker —

Well, keep in mind that over the last couple of years we have made some significant investments to value added things primarily on the broad leaf side, where we have — were asked by customers to do certain things for them where again there is nice margins in those and that’s where those investments are now paying paying off for. So that’s why I came down with a bit in this quarter we also that number that is in the current 9-month, that $39 million includes the building that we bought Shank’s. So we’re happy with those numbers you noted, our capex when we maintenance is around $25 million. So we still cover that number, but if we can make investments in tobacco [Technical Issues] as long as it makes sense.

Ann Gurkin — Davenport & Company LLC — Analyst

Okay. Can you just give a worldwide uncommitted number leaf number?

Candace Formacek — Vice President and Treasurer

Sure, Ann. We’ve got the new worldwide as of 12/31 ’21 is 55 million kilos which is down $18 million from the June 30, ’21 number.

Ann Gurkin — Davenport & Company LLC — Analyst

Okay. And then last, I don’t know if you all can share any insight, it looks like April the FDA is going to come out or announce plans perhaps about how they approach to menthol — use menthol on cigarettes and then characterizing flavors in cigars. Are you making any preparations? Are you seeing any changes in customer orders or inventory levels, are you engaged in comments with the FDA? Any insight into this potential update from FDA in April, anything you can share.

Unidentified Speaker —

No, we’ve not really seen any change to customer patterns, again if we — when we talk to our regulatory folks, they say this is going to be a long drawn process and will take between the brands and the commentary period and litigation. It’s going to take a long time for any of these rules to come into effect.

Ann Gurkin — Davenport & Company LLC — Analyst

Okay, that’s great. That’s all I have. Thank you all for all your time. Appreciate it.

Unidentified Speaker —

Thanks, Ann.

Unidentified Speaker —

Thanks, Ann.

Operator

Thank you, Ms Gurkin. [Operator Instructions]. The next question is from the line of Chris Reynolds with Neuberger Berman. Your line is open.

Chris Reynolds — Neuberger Berman — Analyst

Good evening and thank you for taking my question. I apologize I was not on the first part of your call, but I just wanted to clarify any comments that you might have made about your dividend? You’re one of the dividend aristocrats and you continue to modestly grow that dividend, but you’re diversifying and obviously doing a good job with those investments. And I just wanted to make sure that there wasn’t any change in your longstanding dividend policy for shareholders?

Unidentified Speaker —

Sure. When we announced our capital allocation strategy two years ago, I think our number — my number one thing was investing in our tobacco business by number 2 thing was, maintaining our dividend and growing it annually. So that is, that is a core of our corporate strategy.

Chris Reynolds — Neuberger Berman — Analyst

Okay, thank you so much. Nice results.

Unidentified Speaker —

Thank you.

Operator

Thank you, Mr. Reynolds. There are no additional questions waiting at this time. I will now turn the conference over to the presenters for any closing remarks.

Candace Formacek — Vice President and Treasurer

Thank you very much this evening, and thanks all of you for joining us. We will talk with you next quarter. Thank you.

Operator

[Operator Closing Remarks]

Disclaimer

This transcript is produced by AlphaStreet, Inc. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. This transcript is provided as is without express or implied warranties of any kind. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc.

© COPYRIGHT 2021, AlphaStreet, Inc. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top